ArticleCureus2025
Ectopic Acromegaly Caused by Peripheral Ectopic Growth Hormone Hypersecretion: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acromegaly is most commonly caused by a growth hormone (GH)-secreting pituitary adenoma. In exceptionally rare circumstances, pituitary imaging fails to reveal an adenoma, thereby raising suspicion for ectopic acromegaly. Here, we report the case of a 70-year-old patient who presented for evaluation of headaches and glycemic control. Investigations confirmed ectopic acromegaly due to peripheral GH secretion. The source of GH secretion was a probable digestive neuroendocrine tumor (NET). Given the patient's refusal of surgical intervention, treatment with a somatostatin analog was initiated, resulting in glycemic control consistent with the targets defined according to the patient's age and comorbidities. Insulin-like growth factor 1 (IGF-1) levels subsequently normalized. The diagnosis of GH-secreting ectopic acromegaly is based on correlating clinical manifestations with biochemical evidence of GH excess and appropriate imaging studies. Management is largely driven by surgical removal of the responsible lesion when possible, complemented by somatostatin analogs when indicated. The epidemiology and pertinent literature of this uncommon condition are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.